Cargando…
Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
PURPOSE: Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. METHODS: This desc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116476/ https://www.ncbi.nlm.nih.gov/pubmed/37079089 http://dx.doi.org/10.1007/s00520-023-07742-2 |
_version_ | 1785028432253419520 |
---|---|
author | Uslu, Yasemin Kocatepe, Vildan Sezgin, Derya Subaşı Uras, Cihan |
author_facet | Uslu, Yasemin Kocatepe, Vildan Sezgin, Derya Subaşı Uras, Cihan |
author_sort | Uslu, Yasemin |
collection | PubMed |
description | PURPOSE: Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. METHODS: This descriptive, prospective study was conducted in 2019–2020 with the participation of 531 women who survived breast cancer and were under follow-up at the Senology Institute of a hospital in Istanbul. Inclusion criteria were having completed treatment for early hormone receptor-positive breast cancer, being prescribed tamoxifen, and being 18 years or older. Data were collected using a patient information form and the Morisky Medication Adherence Scale-8 (MMAS-8). RESULTS: The mean age of the participants was 44.9 ± 6.5 years, and the mean duration of tamoxifen use was 834.4 ± 685.7 days. The women’s mean MMAS-8 score was 6.86 ± 1.39. Medication adherence was significantly positively correlated with current age (p = 0.006) and age at diagnosis (p = 0.002). There was a statistically significant difference between tamoxifen adherence according to participants’ employment status (p = 0.028), chronic disease status (p = 0.018), loss of libido (p = 0.012), treatment-related changes in mood changes (p = 0.004), and having negative effects affecting daily life (p < 0.001). CONCLUSION: Overall, breast cancer survivors in this study reported moderate adherence to tamoxifen. The women’s individual characteristics and the adverse effects of treatment influenced medication adherence. Healthcare professionals can help increase adherence to this treatment, which reduces the risk of mortality, by explaining the importance of the medication, identifying and eliminating barriers to adherence, and informing women about evidence-based interventions to increase medication compliance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07742-2. |
format | Online Article Text |
id | pubmed-10116476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101164762023-04-25 Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors Uslu, Yasemin Kocatepe, Vildan Sezgin, Derya Subaşı Uras, Cihan Support Care Cancer Research PURPOSE: Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. METHODS: This descriptive, prospective study was conducted in 2019–2020 with the participation of 531 women who survived breast cancer and were under follow-up at the Senology Institute of a hospital in Istanbul. Inclusion criteria were having completed treatment for early hormone receptor-positive breast cancer, being prescribed tamoxifen, and being 18 years or older. Data were collected using a patient information form and the Morisky Medication Adherence Scale-8 (MMAS-8). RESULTS: The mean age of the participants was 44.9 ± 6.5 years, and the mean duration of tamoxifen use was 834.4 ± 685.7 days. The women’s mean MMAS-8 score was 6.86 ± 1.39. Medication adherence was significantly positively correlated with current age (p = 0.006) and age at diagnosis (p = 0.002). There was a statistically significant difference between tamoxifen adherence according to participants’ employment status (p = 0.028), chronic disease status (p = 0.018), loss of libido (p = 0.012), treatment-related changes in mood changes (p = 0.004), and having negative effects affecting daily life (p < 0.001). CONCLUSION: Overall, breast cancer survivors in this study reported moderate adherence to tamoxifen. The women’s individual characteristics and the adverse effects of treatment influenced medication adherence. Healthcare professionals can help increase adherence to this treatment, which reduces the risk of mortality, by explaining the importance of the medication, identifying and eliminating barriers to adherence, and informing women about evidence-based interventions to increase medication compliance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-023-07742-2. Springer Berlin Heidelberg 2023-04-20 2023 /pmc/articles/PMC10116476/ /pubmed/37079089 http://dx.doi.org/10.1007/s00520-023-07742-2 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Uslu, Yasemin Kocatepe, Vildan Sezgin, Derya Subaşı Uras, Cihan Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title | Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title_full | Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title_fullStr | Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title_full_unstemmed | Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title_short | Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
title_sort | adherence to adjuvant tamoxifen and associated factors in breast cancer survivors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116476/ https://www.ncbi.nlm.nih.gov/pubmed/37079089 http://dx.doi.org/10.1007/s00520-023-07742-2 |
work_keys_str_mv | AT usluyasemin adherencetoadjuvanttamoxifenandassociatedfactorsinbreastcancersurvivors AT kocatepevildan adherencetoadjuvanttamoxifenandassociatedfactorsinbreastcancersurvivors AT sezginderyasubası adherencetoadjuvanttamoxifenandassociatedfactorsinbreastcancersurvivors AT urascihan adherencetoadjuvanttamoxifenandassociatedfactorsinbreastcancersurvivors |